FDA Moves to Kill Compounded GLP-1s for Good — What It Means for Your Options
If you're currently using a compounded GLP-1 medication, this is the most important regulatory development since the FDA first declared drug shortages resolved in late 2024. Here's what actually changed, what hasn't, and what you should do now.
What the FDA Actually Proposed
On April 30, 2026, the FDA announced it is proposing to formally exclude semaglutide (the active ingredient in Ozempic and Wegovy), tirzepatide (Mounjaro and Zepbound), and liraglutide (Victoza and Saxenda) from the 503B outsourcing facility bulk drug substances list.
This is a rulemaking proposal, not an immediate ban. There's a critical distinction between two types of compounding pharmacies:
| Type | What They Do | Impact of This Rule |
|---|---|---|
| 503B Outsourcing Facilities | Manufacture compounded drugs in bulk, with or without a patient-specific prescription | Would be prohibited from compounding semaglutide, tirzepatide, or liraglutide from bulk substances |
| 503A Pharmacies | Compound individual prescriptions for a specific patient | Not directly affected by this proposal — can continue compounding with a valid patient-specific prescription |
The FDA cited more than 455 adverse event reports linked to compounded semaglutide and over 320 linked to compounded tirzepatide, many involving dosing errors from patients self-administering from multi-dose vials.
What This Means for Current Compounded GLP-1 Users
Nothing changes immediately. This is a proposed rule with a public comment period open through June 29, 2026. Finalization could take months. But the direction is clear: the FDA views bulk compounding of these medications as no longer justified now that brand-name supply has stabilized.
If you're on a compounded GLP-1 through a telehealth provider, here's what to watch for:
Providers already pivoting to brand-name: Hims & Hers announced in March 2026 a partnership with Novo Nordisk to offer brand-name semaglutide to subscribers. Other major telehealth platforms are following suit.
The 503A loophole: Individual pharmacies compounding per-patient prescriptions are not targeted by this rule. Some telehealth companies may route patients through 503A pharmacies, though the FDA has signaled it's watching for workarounds.
Additive-based formulations: Research firm IQVIA reported that over 80% of compounded semaglutide and tirzepatide prescriptions now include supplemental ingredients like B vitamins or levocarnitine. These "differentiated" formulations may provide a rationale for continued compounding, though the FDA's stance on this remains ambiguous.
Your Options If Compounding Goes Away
The brand-name market has changed dramatically since 2023. Here's what's available now:
| Option | Medication | Monthly Cost (Self-Pay) | Format |
|---|---|---|---|
| Wegovy Pill | Semaglutide | $149–$299/mo | Daily oral tablet |
| Foundayo | Orforglipron | From $149/mo | Daily oral pill |
| Zepbound via LillyDirect | Tirzepatide | $299–$449/mo | Weekly injection (vial) |
| Wegovy Injectable | Semaglutide | $349/mo ($199 first 2 mo) | Weekly injection (pen) |
| With Insurance | Various | As low as $25/mo | Varies |
| Medicare Part D (July 2026) | Various | $50/mo | Varies |
What Should You Do Right Now?
Don't panic. You have at minimum several months before any rule is finalized. Use this time to explore your options.
Ask your provider about transition plans. Any legitimate telehealth provider should be developing a brand-name pathway for patients. If they aren't discussing this, that's a red flag.
Check your insurance. Coverage for GLP-1 medications has expanded in many 2026 plans. Even if you were denied before, it's worth checking again — especially with Zepbound's FDA approval for obstructive sleep apnea creating new coverage pathways.
Consider oral options. If the injection is the part you tolerate least, both Wegovy pill and Foundayo offer FDA-approved oral alternatives that didn't exist 6 months ago.
Telehealth Providers Still Offering Compounded GLP-1 Access
While the regulatory landscape shifts, these vetted telehealth providers continue to offer access to GLP-1 programs — including both compounded and brand-name pathways where available:
The Public Comment Period
The FDA has opened public comments through June 29, 2026 via the federal docket. If you believe compounded GLP-1s should remain available, this is your opportunity to formally weigh in. The FDA is required to review and respond to substantive public comments before finalizing the rule.
We'll update this article as the rulemaking process moves forward.